TBF1.F - Canntab Therapeutics Limited

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Canntab Therapeutics Limited

223 Riviera Drive
Suite 801
Markham, ON L3R 5J6
Canada
416-957-6303
http://canntab.ca

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey W. RenwickCEO & DirectorN/AN/A1968
Mr. Richard C. GoldsteinCFO & DirectorN/AN/A1961
Mr. Barry M. PolisukChairman & Corp. Sec.N/AN/A1960
Mr. Robert LeflerDirector of OperationsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Canntab Therapeutics Limited, a cannabis oral dosage formulation company, researches and develops advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers extended release, flash melt, immediate release, modified release, and bi-layered tablets for treating sleep disorders, posttraumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. The company was formerly known as Telferscot Resources Inc. and changed its name to Canntab Therapeutics Limited in April 2018. Canntab Therapeutics Limited was incorporated in 2010 and is headquartered in Markham, Canada.

Corporate Governance

Canntab Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.